Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 07:41pm CET
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 JOHNSON & JOHNSON : The Woodrow Wilson Center (WWC) - Discussion
12/02 HIP DAMAGES : Jury tells J&J to pay another $1 billion
12/02 JOHNSON & JOHNSON : to pay $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : J&J ordered to pay record $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : Dallas Jury Returns $1 Billion-Plus Verdict in Defective DeP..
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/29 WPP : Acquires US Company Promotion Execution Partners
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
More news
Sector news : Pharmaceuticals - NEC
12/02 Pharma execs weigh in on possible changes under Trump
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
12/01 GLAXOSMITHKLINE : GSK biotech asthma drug wins UK approval after extra price cut
12/01 PERRIGO : Cohen's SAC Capital in $135 million settlement with Elan investors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/02 J&J Actelion bid reportedly tops $250/share
12/02 GILEAD : M&A Coming Soon
12/02 WALL STREET BREAKFAST : Non-Farm Payrolls In Focus
12/01 Johnson & Johnson hit with $1B-plus jury verdict on faulty hip implants
12/01 With 2016 Nearing A Close, Our Dividend Growth Portfolio Is Up Almost 10%
Advertisement
Financials ($)
Sales 2016 72 061 M
EBIT 2016 22 017 M
Net income 2016 16 371 M
Finance 2016 18 064 M
Yield 2016 2,80%
P/E ratio 2016 18,94
P/E ratio 2017 16,70
EV / Sales 2016 3,98x
EV / Sales 2017 3,70x
Capitalization 304 591 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
More Results